Synthesis, docking study, and structure-activity relationship of novel niflumic acid derivatives acting as anticancer agents by inhibiting VEGFR or EGFR tyrosine kinase activities


	The Crystal ligand (Erlotinib) docked in EGFR tyrosine kinase, hydrogen bonds (green lines) while the pi interactions are shown in purple lines, with mapping surface showing the crystal ligand dominating the active site of EGFR tyrosine kinase.

Part of: Yaseen Y, Kubba A, Shihab W, Tahtamouni L (2022) Synthesis, docking study, and structure-activity relationship of novel niflumic acid derivatives acting as anticancer agents by inhibiting VEGFR or EGFR tyrosine kinase activities. Pharmacia 69(3): 595-614. https://doi.org/10.3897/pharmacia.69.e86504